1352244-23-5

Basic information

• Product Name: 4-(4-methylpiperazin-1-yl)-3-vinylphenylamine
• Synonyms: 4-(4-methylpiperazin-1-yl)-3-vinylphenylamine
• CAS NO: 1352244-23-5
• Molecular Weight: 217.314
• Mol File: 1352244-23-5.mol

Chemical Properties

• CAS DataBase Reference: 4-(4-methylpiperazin-1-yl)-3-vinylphenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-methylpiperazin-1-yl)-3-vinylphenylamine(1352244-23-5)
• EPA Substance Registry System: 4-(4-methylpiperazin-1-yl)-3-vinylphenylamine(1352244-23-5)

Safety Data

• Hazardous Substances Data: 1352244-23-5(Hazardous Substances Data)

Upstream product

• 109-01-3 1-methyl-piperazine 
• 477846-54-1 1-(2-bromo-4-nitrobenzene)-4-methylpiperazine 
• 1352244-80-4 1-methyl-4-(4-nitro-2-vinylphenyl)piperazine 
• 701-45-1 2-bromo-1-fluoro-4-nitrobenzene 

Downstream Products

• 1352244-32-6 4-bromo-2-(5-chloro-2-[4-(4-methylpiperazin-1-yl)-3-vinylphenylamino]pyrimidin-4-ylamino)benzoic acid methyl ester 
• 1352244-33-7 N₄-[5-bromo-2-(propane-2-sulfonyl)phenyl]-5-chloro-N₂-[4-(4-methylpiperazin-1-yl)-3-vinylphenyl]pyrimidine-2,4-diamine 
• 1352244-34-8 N-(4-bromo-2-{5-chloro-2-[4-(4-methylpiperazin-1-yl)-3-vinylphenylamino]pyrimidin-4-ylamino}phenyl)-N-methylmethanesulfonamide 

Relevant articles and documents

Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.13,7.1 9,13]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles

A novel set of 2,4,8,22-tetraazatetracyclo[14.3.1.13,7.1 9,13]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles were prepared as potential anaplastic lymphoma kinase (ALK) inhibitors, designed to rigidly lock an energy-minimized bioactive conformation of the diaminopyrimidine (DAP) scaffold, a well-documented kinase platform. From 13 analogues prepared, macrocycle 2m showed the most promising in vitro ALK enzymatic (IC50 = 0.5 nM) and cellular (IC50 = 10 nM) activities. In addition, macrocycle 2m exhibited a favorable kinase selectivity preference for inhibition of ALK relative to the highly homologous insulin receptor (IR) kinase (IR/ALK ratio of 173). The inclusive in vitro biological results for this set of macrocycles validate this scaffold as a viable kinase template and further corroborate recent DAP/ALK solid state studies indicating that the inverted "U" shaped conformation of the acyclic DAPs is a preferred bioactive conformation.

MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS

The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.